• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

SETBP1突变在骨髓增生异常综合征、慢性粒单核细胞白血病和慢性中性粒细胞白血病中的预后意义：一项荟萃分析。

Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: A meta-analysis.

作者信息

Shou Li-Hong, Cao Dan, Dong Xiao-Hui, Fang Qiu, Wu Ying, Zhang Yan, Fei Ju-Ping, Xu Bao-Lian

机构信息

Department of Hematology, Huzhou Central Hospital, Huzhou, Zhejiang, China.

出版信息

PLoS One. 2017 Feb 3;12(2):e0171608. doi: 10.1371/journal.pone.0171608. eCollection 2017.

DOI:10.1371/journal.pone.0171608
PMID:28158286
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5291491/
Abstract

OBJECTIVES

This meta-analysis investigates the prognostic effect of SET binding protein 1 (SETBP1) mutations in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or chronic neutrophilic leukemia (CNL).

METHODS

Eligible studies from Pubmed, Embase, and Web of Science were searched from database inception through April 2016. Hazard ratios (HRs) and 95% confidence interval (CI) of overall survival (OS) were pooled to calculate the prognostic significance of SETBP1 mutation in patients.

RESULTS

A total of 12 studies with 2321 patients were included in this meta-analysis; 4 studies for MDS, 5 studies for CMML, and 3 studies for CNL. Pooled results suggested that MDS and CMML patients with SETBP1 mutations had a significantly poorer prognosis when compared with patients with wild-type SETBP1 (MDS: HR = 1.808, 95% CI (1.218-2.685), P = 0.001; CMML: HR = 2.223, 95% CI (1.493-3.308), P<0.001). SETBP1 mutations in CNL patients however, showed no significant effect on the overall survival (HR = 1.773, 95% CI (0.877-3.582), P = 0.111). The Begg's and Egger's tests did not show significant publication bias in any groups.

CONCLUSIONS

Current evidence shows that SETBP1 mutation is associated with a poor prognosis in patients with MDS and CMML, but not in patients with CNL.

摘要

目的

本荟萃分析旨在研究SET结合蛋白1（SETBP1）突变对骨髓增生异常综合征（MDS）、慢性粒单核细胞白血病（CMML）或慢性嗜中性粒细胞白血病（CNL）患者的预后影响。

方法

检索了从数据库建立至2016年4月期间来自PubMed、Embase和Web of Science的符合条件的研究。汇总总生存（OS）的风险比（HRs）和95%置信区间（CI），以计算SETBP1突变对患者的预后意义。

结果

本荟萃分析共纳入12项研究，涉及2321例患者；其中4项研究针对MDS，5项研究针对CMML，3项研究针对CNL。汇总结果表明，与野生型SETBP1患者相比，SETBP1突变的MDS和CMML患者预后明显较差（MDS：HR = 1.808，95%CI（1.218 - 2.685），P = 0.001；CMML：HR = 2.223，95%CI（1.493 - 3.308），P<0.001）。然而，CNL患者中的SETBP1突变对总生存无显著影响（HR = 1.773，95%CI（0.877 - 3.582），P = 0.111）。Begg检验和Egger检验在任何组中均未显示出显著的发表偏倚。

结论

目前的证据表明，SETBP1突变与MDS和CMML患者的不良预后相关，但与CNL患者无关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed73/5291491/d10255453f00/pone.0171608.g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed73/5291491/9fa2cd6d9ea7/pone.0171608.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed73/5291491/c3046a4110de/pone.0171608.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed73/5291491/e29df38014a4/pone.0171608.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed73/5291491/380ec11e1141/pone.0171608.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed73/5291491/f0a15af03281/pone.0171608.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed73/5291491/1f667403e695/pone.0171608.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed73/5291491/83fcbd74a959/pone.0171608.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed73/5291491/5235cbb4b1e3/pone.0171608.g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed73/5291491/9b0e4165c2e3/pone.0171608.g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed73/5291491/d10255453f00/pone.0171608.g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed73/5291491/9fa2cd6d9ea7/pone.0171608.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed73/5291491/c3046a4110de/pone.0171608.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed73/5291491/e29df38014a4/pone.0171608.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed73/5291491/380ec11e1141/pone.0171608.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed73/5291491/f0a15af03281/pone.0171608.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed73/5291491/1f667403e695/pone.0171608.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed73/5291491/83fcbd74a959/pone.0171608.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed73/5291491/5235cbb4b1e3/pone.0171608.g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed73/5291491/9b0e4165c2e3/pone.0171608.g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed73/5291491/d10255453f00/pone.0171608.g010.jpg

相似文献

1
Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: A meta-analysis.SETBP1突变在骨髓增生异常综合征、慢性粒单核细胞白血病和慢性中性粒细胞白血病中的预后意义：一项荟萃分析。
PLoS One. 2017 Feb 3;12(2):e0171608. doi: 10.1371/journal.pone.0171608. eCollection 2017.
2
Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia.CSF3R、SRSF2和SETBP1突变在慢性嗜中性粒细胞白血病和慢性粒单核细胞白血病中的临床意义
Oncotarget. 2017 Mar 28;8(13):20834-20841. doi: 10.18632/oncotarget.15355.
3
Prognostic significance of ASXL1 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: A meta-analysis.髓系发育异常综合征和慢性粒单核细胞白血病中ASXL1突变的预后意义：一项荟萃分析。
Hematology. 2016 Sep;21(8):454-61. doi: 10.1080/10245332.2015.1106815. Epub 2016 Mar 4.
4
ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia.ASXL1 突变在 CSF3R 突变的慢性中性粒细胞白血病中频繁发生且具有预后不良影响。
Am J Hematol. 2015 Jul;90(7):653-6. doi: 10.1002/ajh.24031.
5
Prognostic significance of SRSF2 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: a meta-analysis.SRSF2突变在骨髓增生异常综合征和慢性粒单核细胞白血病中的预后意义：一项荟萃分析
Hematology. 2018 Dec;23(10):778-784. doi: 10.1080/10245332.2018.1471794. Epub 2018 May 14.
6
CSF3R T618I, SETBP1 G870S, SRSF2 P95H, and ASXL1 Q780* tetramutation co-contribute to myeloblast transformation in a chronic neutrophilic leukemia.CSF3R T618I、SETBP1 G870S、SRSF2 P95H和ASXL1 Q780*四重突变共同促成慢性嗜中性粒细胞白血病中的成髓细胞转化。
Ann Hematol. 2021 Jun;100(6):1459-1461. doi: 10.1007/s00277-021-04491-2. Epub 2021 Apr 6.
7
Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML.无外周血单核细胞增多但有骨髓单核细胞增多证据的骨髓增生异常综合征与慢性粒-单核细胞白血病具有共同的临床和分子特征。
Leuk Res. 2018 Feb;65:1-4. doi: 10.1016/j.leukres.2017.12.002. Epub 2017 Dec 5.
8
RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.RAS 突变有助于慢性髓单核细胞白血病向增生性变异型的演变。
Clin Cancer Res. 2010 Apr 15;16(8):2246-56. doi: 10.1158/1078-0432.CCR-09-2112. Epub 2010 Apr 6.
9
SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias.658例骨髓增生异常综合征、慢性粒单核细胞白血病和继发性急性髓系白血病患者中的SETBP1突变
Leukemia. 2013 Jun;27(6):1401-3. doi: 10.1038/leu.2013.35. Epub 2013 Feb 5.
10
Chronic neutrophilic leukemia preceded by myelodysplastic syndromes.以骨髓增生异常综合征为前驱的慢性嗜中性粒细胞白血病。
Int J Hematol. 2023 Nov;118(5):636-641. doi: 10.1007/s12185-023-03636-5. Epub 2023 Jul 13.

引用本文的文献

1
Chronic Neutrophilic Leukemia: Advances in Diagnosis, Genetic Insights, and Management Strategies.慢性中性粒细胞白血病：诊断、遗传学见解及管理策略的进展
Cancers (Basel). 2025 Jan 12;17(2):227. doi: 10.3390/cancers17020227.
2
Infrequent Presentations of Chronic -Mutated Myeloid Neoplasms: Clinicopathological Features of Eight Cases from a Single Institution and Review of the Literature.慢性突变型髓系肿瘤的罕见表现：来自单一机构的8例临床病理特征及文献复习
Cancers (Basel). 2024 Feb 7;16(4):705. doi: 10.3390/cancers16040705.
3
Research progress of additional pathogenic mutations in chronic neutrophilic leukemia.

本文引用的文献

1
Prognostic significance of ASXL1 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: A meta-analysis.髓系发育异常综合征和慢性粒单核细胞白血病中ASXL1突变的预后意义：一项荟萃分析。
Hematology. 2016 Sep;21(8):454-61. doi: 10.1080/10245332.2015.1106815. Epub 2016 Mar 4.
2
Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents.在对去甲基化药物有反应的慢性粒单核细胞白血病中，突变等位基因负担保持不变。
Nat Commun. 2016 Feb 24;7:10767. doi: 10.1038/ncomms10767.
3
Age-related mutations and chronic myelomonocytic leukemia.
慢性中性粒细胞白血病中附加致病性突变的研究进展。
Ann Hematol. 2024 Aug;103(8):2591-2600. doi: 10.1007/s00277-023-05550-6. Epub 2023 Nov 22.
4
SETBP1 is dispensable for normal and malignant hematopoiesis.SETBP1 对于正常和恶性造血是可有可无的。
Leukemia. 2023 Sep;37(9):1802-1811. doi: 10.1038/s41375-023-01970-5. Epub 2023 Jul 18.
5
Autoimmune hemolytic anemia complicating a chronic neutrophilic leukemia: A case report of a rare association.自身免疫性溶血性贫血合并慢性中性粒细胞白血病：一例罕见关联的病例报告
Clin Case Rep. 2023 May 26;11(6):e7432. doi: 10.1002/ccr3.7432. eCollection 2023 Jun.
6
Case report: Chronic neutrophilic leukemia associated with monoclonal gammopathies. A case series and review of genetic characteristics and practical management.病例报告：与单克隆丙种球蛋白病相关的慢性中性粒细胞白血病。病例系列及遗传特征与实际管理的综述
Front Oncol. 2022 Dec 7;12:1014671. doi: 10.3389/fonc.2022.1014671. eCollection 2022.
7
CNL and aCML should be considered as a single entity based on molecular profiles and outcomes.CNL 和 aCML 应基于分子谱和结果被视为单一实体。
Blood Adv. 2023 May 9;7(9):1672-1681. doi: 10.1182/bloodadvances.2022008204.
8
The genetics of myelodysplastic syndromes and the opportunities for tailored treatments.骨髓增生异常综合征的遗传学及个性化治疗的机遇
Front Oncol. 2022 Oct 20;12:989483. doi: 10.3389/fonc.2022.989483. eCollection 2022.
9
Chronic Neutrophilic Leukemia: A Comprehensive Review of Clinical Characteristics, Genetic Landscape and Management.慢性中性粒细胞白血病：临床特征、遗传图谱及治疗的综合综述
Front Oncol. 2022 Apr 14;12:891961. doi: 10.3389/fonc.2022.891961. eCollection 2022.
10
Mutated SETBP1 activates transcription of Myc programs to accelerate CSF3R-driven myeloproliferative neoplasms.突变的 SETBP1 激活 Myc 程序的转录，从而加速 CSF3R 驱动的骨髓增殖性肿瘤。
Blood. 2022 Aug 11;140(6):644-658. doi: 10.1182/blood.2021014777.
与年龄相关的突变和慢性粒单核细胞白血病。
Leukemia. 2016 Apr;30(4):906-13. doi: 10.1038/leu.2015.337. Epub 2015 Dec 9.
4
ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia.ASXL1 突变在 CSF3R 突变的慢性中性粒细胞白血病中频繁发生且具有预后不良影响。
Am J Hematol. 2015 Jul;90(7):653-6. doi: 10.1002/ajh.24031.
5
Correlation of myelodysplastic syndromes with i(17)(q10) and TP53 and SETBP1 mutations.骨髓增生异常综合征与i(17)(q10)以及TP53和SETBP1突变的相关性
Br J Haematol. 2015 Oct;171(1):137-41. doi: 10.1111/bjh.13355. Epub 2015 Feb 25.
6
Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome.慢性粒单核细胞白血病中的 blast 转化：危险因素、遗传特征、生存和治疗结果。
Am J Hematol. 2015 May;90(5):411-6. doi: 10.1002/ajh.23962. Epub 2015 Apr 1.
7
[CSF3R, ASXL1,SETBP1, JAK2 V617F and CALR mutations in chronic neutrophilic leukemia].慢性嗜中性粒细胞白血病中的CSF3R、ASXL1、SETBP1、JAK2 V617F和CALR突变
Zhonghua Xue Ye Xue Za Zhi. 2014 Dec;35(12):1069-73. doi: 10.3760/cma.j.issn.0253-2727.2014.12.005.
8
SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS.SETBP1突变驱动ASXL1突变的骨髓增生异常综合征中的白血病转化。
Leukemia. 2015 Apr;29(4):847-57. doi: 10.1038/leu.2014.301. Epub 2014 Oct 13.
9
ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.ASXL1 和 SETBP1 基因突变及其对慢性粒单核细胞白血病的预后贡献：来自 466 例患者的两项中心研究。
Leukemia. 2014 Nov;28(11):2206-12. doi: 10.1038/leu.2014.125. Epub 2014 Apr 3.
10
Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression.SETBP1 突变对原发性骨髓增生异常综合征患者的临床意义及其在疾病进展过程中的稳定性。
Am J Hematol. 2014 Feb;89(2):181-6. doi: 10.1002/ajh.23611. Epub 2013 Nov 20.